Why the study?
The relationship of dyslipidemia with AF-related stroke is not clear, leaving it unanswered whether patients with AF-related stroke should unanimously receive lipid-lowering agents.
Do statins improve outcomes in patients with atrial fibrillation-related stroke?
Do statins improve outcomes in patients with atrial fibrillation-related stroke?
Statins may offer protective benefits regarding stroke severity and survival in patients with AF-related stroke, and overall cardiovascular risk should guide LDL-C targeted therapy.
Answers are grounded in this paper and cite their sources.
May support statin pretreatment in AF-stroke; leaves open confirmation of outcome benefits in randomized trials.
The relationship of dyslipidemia with atrial fibrillation (AF)-related stroke is not clear. The question whether patients with AF-related stroke should receive lipid lowering agents unanimously remains unanswered. Treatment with statins does not appear to be as protective as initially thought in terms of AF prevention; however, certain groups of patients may benefit from statin use. There is evidence that statins favorably affect stroke severity, in-hospital mortality, prognosis and survival of patients with AF-related stroke. Statin pretreatment is associated with better collateral circulation in patients with cardioembolic stroke. Importantly, AF frequently co-exists with several cardiovascular comorbidities, while patients with AF-related stoke may be prone to other cardiovascular events. The overall cardiovascular risk should be assessed in AF patients experiencing a stroke and treated in accordance with the proposed low density lipoprotein cholesterol (LDL-C) targets.
No takes yet. Share an insight, caveat, or question.
Florentin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: